NEW YORK (GenomeWeb News) – Exiqon and Asuragen announced today the signing of a service center agreement allowing Asuragen to offer real-time PCR services based on Exiqon's miRcury LNA Universal RT-microRNA PCR products.
Exiqon's technology is used for discovering new biomarkers of diseases and biological processes and combines Universal RT reaction with LNA-enhanced PCR primers. Asuragen Genomic Services Division provides nucleic acid-based services, including biomarker discovery and companion diagnostic development.
Financial and other terms of the deal were not disclosed.
"Exiqon's high-quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners," Carol Berry, SVP and GM of Asuragen Genomic Services Division, said in a statement.